91.79
+0.1106(+0.12%)
Currency In USD
| Previous Close | 91.68 |
| Open | 91.83 |
| Day High | 92.56 |
| Day Low | 90.37 |
| 52-Week High | 99.5 |
| 52-Week Low | 52.5 |
| Volume | 128,876 |
| Average Volume | 475,701 |
| Market Cap | 1.99B |
| PE | -133.03 |
| EPS | -0.69 |
| Moving Average 50 Days | 88.43 |
| Moving Average 200 Days | 68.9 |
| Change | 0.11 |
If you invested $1000 in ANI Pharmaceuticals, Inc. (ANIP) 10 years ago, it would be worth $2,001.98 as of October 08, 2025 at a share price of $91.791. Whereas If you bought $1000 worth of ANI Pharmaceuticals, Inc. (ANIP) shares 5 years ago, it would be worth $3,040.43 as of October 08, 2025 at a share price of $91.791.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 25, 2025 8:30 PM GMT
PRINCETON, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadershi
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
GlobeNewswire Inc.
Aug 01, 2025 10:50 AM GMT
PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the mar
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
GlobeNewswire Inc.
Jul 23, 2025 10:50 AM GMT
Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled Treatment-Naïve, or Almost Naïve, Patients with DME Results presented by Michael A. Singer, M.D. in a